Abstract
Psoriasis is a common chronic inflammatory immune-mediated skin disease which affects 3% of the US population and remains undertreated. This study examined utilization rates and time-to-treatment initiation of first-line therapy among newly diagnosed, commercially insured patients.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
